Clinical Trial Update: Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial comparing neoadjuvant Fruquintinib plus Tislelizumab with modified CapeOX versus CapeOX for locally advanced rectal cancer; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Fruquintinib (fruquintinib)
• Modified CapeOX regimen (mCapeOX)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Rectal Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING